繁體
简体中文
繁體中文

GraniteShares 2x Long NTAP Daily ETF NTAL 深 滬

已收盤 11-20 16:00:00 美东时间

19.9538

-3.609

-15.32%

华盛通華盛通
立即下載
  • 最 高21.28
  • 今 開21.28
  • 成交量 276股
  • 最 低 19.9538
  • 昨 收 23.5631
  • 總市值 59.86万
  • 52周最高 49.64
  • 市盈率 靜 --
  • 換手率 0.92%
  • 52周最低 19.9538
  • 委 比 0.00%
  • 總股本 3.00万
  • 歷史最高 49.64
  • 量 比 0.07
  • 振 幅 5.63%
  • 歷史最低 19.9538
  • 每 手 1
  • 風險率 6.62%

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Baker Hughes and TPAO Explore Industrializing Next-generation Geothermal in Türkiye for Always-on Power Generation

    Baker Hughes and TPAO signed an agreement to explore enhanced geothermal systems (EGS) in Türkiye, supporting the country's goals to reduce emissions and enhance energy security. The deal includes a nationwide assessment of EGS potential, risk evaluation, pilot drilling, and commercial development. EGS technology can unlock new geothermal energy sources, contributing to Türkiye's energy independence and lower-carbon power generation.

    11-12 12:00

  • Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

    Zentalis Pharmaceuticals announced positive survival data from the DENALI Part 1b trial for azenosertib, a potential first-in-class oral therapy for Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI Part 2c enrollment is expected to complete in November 2026, with a topline readout anticipated in the first half of 2027. The company reported $228.9 million in cash as of September 30, 2026, providing runway into the first half of ...

    11-09 21:05

  • CECO Environmental Announces Upcoming Investor Conferences

    CECO Environmental Corp. (TXSE: CECO) announced that CEO Todd Gleason and Vice President Marcio Pinto will present and host meetings at two investor conferences: the Baird 2026 Global Industrial Conference in Chicago on November 10, 2026, and the 18th Annual Southwest Ideas Conference in Dallas on November 19, 2026. Presentation materials will be available on the company's Investor Relations website. CECO, a leading industrial company focused on ...

    11-05 16:45

  • Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

    Zentalis Pharmaceuticals announced that its management team will participate in two upcoming investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026, and Stifel's 2026 Healthcare Conference on November 11, 2026. The company is advancing its first-in-class WEE1 inhibitor, azenosertib, for ovarian cancer treatment. Live webcasts and recordings of the events will be available on the company's website.

    11-03 21:15

  • Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Zentalis Pharmaceuticals granted 136,000 non-qualified stock options to four new employees on November 2, 2026, under the 2022 Inducement Plan. The options have an exercise price of $1.85 per share, a 10-year term, and vest over four years, with 25% vesting after the first year and the remaining 75% in equal monthly installments over the following three years. Continued employment is required for vesting. The company focuses on developing ovarian...

    11-02 22:00

  • 美股夜盘 | GraniteShares 2x Long NTAP Daily ETF涨21.70%,最新股价40.57美元

    GraniteShares 2x Long NTAP Daily ETF涨21.70%,报40.57美元

    11-02 09:42

  • CECO Environmental To Release Third Quarter 2026 Earnings and Host Conference Call on November 9

    CECO Environmental Corp. announced it will release its third quarter 2026 financial results on November 9, 2026, premarket, followed by an earnings call at 8:30 a.m. Eastern Time. The webcast will be available live at https://edge.media-server.com/mmc/p/x4b7b8us, with a replay on the company's website shortly after. CECO, a leading industrial company focused on environmental solutions, serves global markets through its Engineered Systems and Indu...

    10-27 15:00

  • Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

    Zentalis Pharmaceuticals announced interim OS data from the DENALI Part 1b study for azenosertib in platinum-resistant ovarian cancer (PROC). Cyclin E1-positive patients (n=48) had a median OS of 15.8 months, compared to 7.5 months in Cyclin E1-negative patients (n=46). No new safety signals were observed. The data will be presented at the ESMO Congress 2026 on October 23. Azenosertib is being further developed in DENALI Part 2 and the ASPENOVA P...

    10-18 22:05

  • Netapp Expands Cloud Migration Capabilities With AWS Transform Integration

    NetApp, Inc. (NASDAQ:NTAP) shares are trading higher on Thursday after the company reported strong first-quarter results and an upbeat outlook on Wednesday. Today, NetApp, along with Amazon Web Services (AWS), disclosed that AWS Transform will now support Amazon FSx for NetApp ONTAP. It will enable ...

    09-03 23:01

  • 美股夜盘 | GraniteShares 2x Long NTAP Daily ETF跌16.83%,最新股价24.2美元

    GraniteShares 2x Long NTAP Daily ETF跌16.83%,报24.2美元

    09-03 11:43